HealthcareCommunication & Collaboration3MediumOccupational Therapist

Clinicians treating 'zebra' conditions lack a HIPAA-compliant, non-Facebook platform to collaborate and share resources.

Facebook requires identity verification (video selfie) that some users find invasive, and it may not meet HIPAA compliance needs for clinical discussions.

Opp. Score

Severity

3Medium

Willingness to Pay

none

Added

Jul 12, 2026

Workarounds Described

uses Facebook groups to share resources and collaborate on patient care
trying to create a Discord server as a workaround to avoid Facebook

Implied Software Gaps

HIPAA-compliant clinical collaboration platform without invasive identity verification
Specialized community platform for clinicians treating rare conditions

App Concept

ZebraLink Clinician Hub

A HIPAA-compliant collaboration platform designed for clinicians treating rare and complex conditions. It offers dedicated channels for different specialties, resource sharing, and secure messaging, replacing ad-hoc Facebook groups that lack privacy and compliance features. Better than Facebook because it is purpose-built for clinical collaboration with built-in HIPAA safeguards and no invasive sign-up procedures.

Key Features

HIPAA-compliant messaging and file sharing
Specialty-specific channels (rehab, cardiology, etc.)
Identity verification via professional credentials, not facial recognition
Resource library for clinical guidelines and case studies

Target Users: Clinicians (OTs, PTs, MDs) treating rare conditions like EDS, Dysautonomia, MCAS, in small to large healthcare settings

Revenue Model: Freemium with $49/mo pro tier for advanced collaboration tools and analytics

Existing Solutions Mentioned

Facebook

Part of App Idea

Clinicians treating 'zebra' conditions lack a HIPAA-compliant, non-Facebook platform to collaborate and share resources.

Want to go deeper?

Sign up to save ideas, run AI analysis, and track opportunities in your personal workspace. Founding members get full access.

Join Beta

Solutions (0)

Discussion (0)

No comments yet